MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 125185 | Name: Fluciclatide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluciclatide is an integrin-targeted PET radiopharmaceutical.

Chemical Structure

Fluciclatide
Fluciclatide
CAS#879894-00-5

Theoretical Analysis

MedKoo Cat#: 125185

Name: Fluciclatide

CAS#: 879894-00-5

Chemical Formula: C75H115FN18O27S3

Exact Mass: 1814.7300

Molecular Weight: 1816.02

Elemental Analysis: C, 49.60; H, 6.38; F, 1.05; N, 13.88; O, 23.79; S, 5.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Fluciclatide; UQ6CV583Q3; AH-111585; UNII-UQ6CV583Q3; Fluciclatide F-18
IUPAC/Chemical Name
2-((1R,4S,10R,13S,16R,19S,25S)-10-((1-amino-1,5-dioxo-3,9,12,15-tetraoxa-6-azaheptadecan-17-yl)carbamoyl)-13-benzyl-4-((E)-1-(4-fluorophenyl)-5,25,29-trioxo-3,9,12,15,18,21,27-heptaoxa-2,6,24,30-tetraazatetratriacont-1-en-34-yl)-25-(3-guanidinopropyl)-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octaazabicyclo[14.11.4]hentriacontan-19-yl)acetic acid
InChi Key
VXFFXZSNVKXXIB-SCSBXPEDSA-N
InChi Code
InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39+/t53-,54-,55-,56-,57-,58-,59-/m0/s1
SMILES Code
NC(COCC(NCCOCCOCCOCCNC([C@@H]1CSCC(N[C@H](C(N[C@H]2CSSC[C@@H](C(N[C@H](C(N1)=O)CC3=CC=CC=C3)=O)NC([C@@H](NC(CNC([C@@H](NC2=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)=O)CCCCNC(COCC(NCCOCCOCCOCCOCCOCCNC(CO/N=C/C4=CC=C(C=C4)F)=O)=O)=O)=O)=O)=O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,816.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mena E, Owenius R, Turkbey B, Sherry R, Bratslavsky G, Macholl S, Miller MP, Somer EJ, Lindenberg L, Adler S, Shih J, Choyke P, Kurdziel K. [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1879-88. doi: 10.1007/s00259-014-2791-x. Epub 2014 Jun 28. PMID: 24973039; PMCID: PMC6336392. 2: Sharma R, Valls PO, Inglese M, Dubash S, Chen M, Gabra H, Montes A, Challapalli A, Arshad M, Tharakan G, Chambers E, Cole T, Lozano-Kuehne JP, Barwick TD, Aboagye EO. [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum- resistant/refractory ovarian cancer. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1239-1251. doi: 10.1007/s00259-019-04532-z. Epub 2019 Nov 21. PMID: 31754793; PMCID: PMC7101300. 3: Tarkin JM, Mason JC, Fayad ZA. Imaging at the inter-face of inflammation and angiogenesis by 18F-fluciclatide PET. Heart. 2019 Dec;105(24):1845-1847. doi: 10.1136/heartjnl-2019-315487. Epub 2019 Aug 30. PMID: 31471464. 4: Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV, Lee JD, Lee KH, O'Doherty MJ, Groves AM, Miller MP, Somer EJ, Coombes CR, Aboagye EO. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. J Nucl Med. 2015 Dec;56(12):1855-61. doi: 10.2967/jnumed.115.158253. Epub 2015 Sep 17. PMID: 26383153. 5: Jenkins WS, Vesey AT, Vickers A, Neale A, Moles C, Connell M, Joshi NV, Lucatelli C, Fletcher AM, Spratt JC, Mirsadraee S, van Beek EJ, Rudd JH, Newby DE, Dweck MR. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis. Heart. 2019 Dec;105(24):1868-1875. doi: 10.1136/heartjnl-2019-315103. Epub 2019 Aug 17. PMID: 31422361; PMCID: PMC6929706.